When measured against the market's most prolific capital-return leaders, Amgen’s ability to maintain this level of ...

Although Amgen has outpaced the Dow over the past year, analysts remain cautiously optimistic about the stock’s prospects.

Amgen Inc. has reached a significant milestone as its stock hit an all-time high of 385.63 USD, with shares currently trading at $386.08, just shy of the 52-week high of $385.12. This achievement ...

Amgen (AMGN) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Amgen (NASDAQ: AMGN) is doing something unusual in 2025. The biotech giant's shares are up 7.2% for the year as I write this while most large-cap healthcare stocks struggle; yet it trades at just 13 ...

Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming patent expirations. Amgen's Q3/25 results showed 12.4% revenue growth, 13.6% ...

Buying $100 In AMGN: If an investor had bought $100 of AMGN stock 15 years ago, it would be worth $739.18 today based on a price of $379.40 for AMGN at the time of writing.

Amgen is a biotech leader with strong sales growth, key products outperforming, and an impressive R&D pipeline fueling future prospects. Despite political headwinds and margin pressures, AMGN raised ...

Both Novo Nordisk NVO and Amgen AMGN are large-cap, innovation-driven healthcare leaders with global scale, strong balance sheets, and a track record of turning scientific breakthroughs into ...